Skip to content Skip to footer
Subscribe Now
Viewpoints_Marcelo Freire
VIEWPOINTS

Takeda at UEG Week 2024: Marcelo Freire from Takeda in an Enlightening Conversation with PharmaShots

Shots:  Recently, Takeda shared 32-week interim results from the VERDICT study, which evaluated Entyvio (vedolizumab) for the treatment of patients with ulcerative colitis (UC)  Entyvio achieved a stringent endpoint of disease clearance, a new concept in UC clinical research, which is a combination of clinical, endoscopic, and histologic remission  Today at PharmaShots, we are joined…
December 2, 2024

Read more

Viewpoints_John Santini
VIEWPOINTS

Fluorescence Visualization in Lung Cancer: John Santini from Vergent Bioscience in Conversation with PharmaShots

Shots:  With the growing significance of minimally invasive surgery comes the need for enhanced visualization to optimize surgical outcomes for both surgeons and patients.  Vergent BioScience’s VGT-309 shows promising potential for tumor visualization during lung cancer surgeries. VGT-309 is an investigational intraoperative molecular imaging (IMI) agent that utilizes near-infrared (NIR) fluorescence imaging to improve precision. …
November 25, 2024

Read more

EMA Marketing Authorization of New Drugs in October 2024
INSIGHTS+

EMA Marketing Authorization of New Drugs in October 2024

Shots:    The EMA’s CHMP has granted positive opinions to 5 Biologics and 1 New Chemical Entity in October 2024, leading to treatments for patients and advances in the healthcare industry   The major highlighted drugs were Novo Nordisk’s Alhemo to treat Haemophilia A or B with inhibitors and AstraZeneca & Ionis’ Wainzua for Hereditary Transthyretin-Mediated Amyloidosis  PharmaShots has…
November 21, 2024

Read more

Viewpoints_Phil Lambert
VIEWPOINTS

Enhancing DMD Care: Phil Lambert from Satellos in a Riveting Conversation with PharmaShots

Shots:  Conventional therapeutic models for Duchenne Muscular Dystrophy (DMD) primarily focus on the role of dystrophin in maintaining muscle cell integrity. However, Satellos’ SAT-3247 takes a novel approach, targeting the lack of dystrophin in muscle stem cells to restore muscle fiber regeneration and repair  Today at PharmaShots, we are joined by Phil Lambert, Chief Scientific…
November 20, 2024

Read more

Announcements

PharmaShots Secures Prestigious Bharat Business Award 2024 

PharmaShots is pleased to announce that we have been honored with the Best Healthcare and Pharma Digital Media Management award under the Bharat Business Awards 2024 category, organized by WEECE Entertainment and Events Pvt. Ltd.  This recognition is a testament to the dedication, resilience, and hard work of our team. We are deeply grateful to our clients for their continued…
November 14, 2024

Read more

Viewpoints_Jason Lerner
VIEWPOINTS

Transcending Epilepsy Care: Jason Lerner from Biohaven in an Enlightening Dialogue Exchange with PharmaShots

Shots:  Epilepsy affects around 1.5 million people in the US and 50 million globally. With approximately 40% of epilepsy patients being drug-resistant, there is an urgent need for innovative therapies  Today, at PharmaShots we have Dr. Jason Lerner from Biohaven shedding light on BHV-7000, an investigational anti-seizure treatment and selective activator of potassium channels in…
November 6, 2024

Read more

Key Biosimilars Events of October 2024
INSIGHTS+

Key Biosimilars Events of October 2024

Shots:       Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency        Biosimilars are expected to be a cost-effective alternative to the high-priced branded biologics, offering significant and much-needed cost savings to both payers and patients        The major highlights were the US FDA’s approval of Dong-A ST’s Imuldosa…
November 5, 2024

Read more

Load more